Fluzone® Quadrivalent

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline, Stanford University, Yale University

Conditions

Healthy AdultsHepatitis AInfluenzaTyphoidVaccine Reaction

Early Phase 1

Intradermal Influenza Vaccination

RecruitingNCT06067555

Yale UniversityVaccine Reaction

Start: 2024-01-24End: 2026-05-31Target: 249Updated: 2025-06-19

Phase 1

Effects of Aging on Primary and Secondary Vaccine Responses

CompletedNCT03312699

Stanford UniversityHealthy Adults, Hepatitis A, Influenza +1

Start: 2017-09-19End: 2023-12-31Updated: 2024-12-16

Phase 3

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

CompletedNCT02242643

GlaxoSmithKlineInfluenza

Start: 2014-10-01End: 2015-06-23Updated: 2018-09-07

Related Papers

Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial.

2017-03-0126 citations

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial.

2015-07-1623 citations